One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand ...
CRISPR gene therapy Casgevy can nearly eliminate sickle cell crises, but difficult stem‑cell collection is delaying access ...
CRISPR gene drives bias inheritance in pests, advancing population-level control while raising questions about resistance and ...
A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...
12d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually by 2050. Now, scientists at UC San Diego have unveiled a powerful new CRISPR ...
For years, researchers have been trying to figure out how to treat inherited blood disorders like sickle cell disease without causing new health problems in the process. Now, a team of scientists from ...
A new light-based sensor detects cancer markers at near-zero concentrations.
The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.
Growing Adoption of Gene Therapy Platforms, Expanding Agricultural Biotechnology Applications, and Accelerating Clinical Trial Activity Drive Robust Market Expansion.Austin, United States, Feb. 27, ...
Revvity's Dharmacon All-in-one lentiviral platform has expanded to include whole-genome library options for CRISPR knockout (CRISPRko), CRISPR interference (CRISPRi), and CRISPR activation (CRISPRa).
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results